Search hospitals > Alaska > Anchorage
Providence Alaska Medical Center
Claim this profileAnchorage, Alaska 99508
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Brain Tumor
Conducts research for Breast cancer
332 reported clinical trials
9 medical researchers
Summary
Providence Alaska Medical Center is a medical facility located in Anchorage, Alaska. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Brain Tumor, Breast cancer and other specialties. Providence Alaska Medical Center is involved with conducting 332 clinical trials across 520 conditions. There are 9 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Brenda J. Wittman, and Nitya Alluri.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Alison K. ConlinProvidence Portland Medical Center6 years of reported clinical research
Expert in Breast Cancer
Expert in Cancer
107 reported clinical trials
183 drugs studied
Charles W. DrescherProvidence Portland Medical Center8 years of reported clinical research
Studies Breast Cancer
Studies Non-Small Cell Lung Cancer
53 reported clinical trials
99 drugs studied
Brenda J. WittmanProvidence Alaska Medical Center8 years of reported clinical research
Expert in Cancer
Expert in Neuroblastoma
35 reported clinical trials
76 drugs studied
Nitya AlluriProvidence Portland Medical Center2 years of reported clinical research
Studies Uterine Cancer
Studies Endometrial Adenocarcinoma
28 reported clinical trials
79 drugs studied
Clinical Trials running at Providence Alaska Medical Center
Lung Cancer
Prostate Cancer
Bladder Cancer
Pancreatic Cancer
Ovarian Cancer
Breast Cancer
Esophageal cancer
Multiple Myeloma
Cancer
Bladder Carcinoma
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Providence Alaska Medical Center?
Providence Alaska Medical Center is a medical facility located in Anchorage, Alaska. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Brain Tumor, Breast cancer and other specialties. Providence Alaska Medical Center is involved with conducting 332 clinical trials across 520 conditions. There are 9 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Brenda J. Wittman, and Nitya Alluri.
Where is Providence Alaska Medical Center located?
**Providence Alaska Medical Center**
- **Address:** 3200 Providence Drive, Anchorage, AK 99508
- **Directions:** Accessible via Seward Highway; exit onto Providence Drive, hospital will be on the left.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at Providence Alaska Medical Center, please contact the Financial Assistance Team at 855-229-6466. For billing customer service regarding clinics and physicians, dial 907-212-6522, and for hospital billing inquiries, call 907-212-6500.
What insurance does Providence Alaska Medical Center accept?
Providence Alaska Medical Center accepts a wide range of insurance plans, including but not limited to Premera, Aetna Medicare Advantage PPO, Anthem Blue Cross HMO/PPO, Blue Shield of CA HMO/PPO, Choice/Humana PPO, Cigna PPO, and United Healthcare PPO. For the most accurate and current information on accepted insurance plans, please contact the hospital directly.
What awards or recognition has Providence Alaska Medical Center received?
Providence Alaska Medical Center, located in Anchorage, Alaska, is honored as a 2023-24 Best Regional Hospital by U.S. News & World Report, excelling in seven types of care. The hospital proudly holds its second Magnet designation, highlighting its commitment to nursing excellence and the positive impact on the community.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.